I wonder has anyone here so far managed to make a positive return from buying $AVXL call options
That is of no interest to me since I have not previously bought AVXL call options. I am just now staking out long call options positions with what I believe are very low break-even points due to my perception of a change in AVXL's business fundamentals and my optimism about favorable Rett's EXCELLENCE results as well as hopes for AD
HINT: Today's stock buy. IOVA just received AH an FDA acceptance of its BLA for Lifileucel for treatment of advanced metastatic and nonresectable melanoma. The FDA granted a six month priority review with a PDUFA data of November 25, 2023. No advisory meeting planned by the FDA. IOVA's stock price traded around $28 prior to the initial rejection of the BLA. The stock price closed today at $7.55. If Lifileucel receives accelerated approval, IOVA will have a confirmatory Phase III trial in frontline advance melanoma that is now recruiting. Most recent February 2023 analyst target issued at $30.